Everything below concerns GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-19. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
==== Democratic reaction ==== The narrow passage of OBBBA led to internal backlash and division in the Democratic Party. Three elderly Democratic representatives (Raúl Grijalva of Arizona, age 77; Sylvester Turner of Texas, age 70; and Gerry Connolly of Virginia, age 75) died in the first five months of 2025. If any of the three had been alive when the vote was taken, the result of the vote could have been different. The vote "quickly reignited an intraparty debate about gerontocracy and aging politicians clinging to power".
In March 2020, the release of 15.ai, a free web application created by an anonymous MIT researcher that could generate convincing character voices using minimal training data, was one of the earliest publicly available uses for generative AI. The platform is credited as the first mainstream service for audio deepfakes. In 2021, DALL-E, a closed-source transformer-based generative model developed by OpenAI, drew widespread attention to text-to-image generation. Other projects, including open-source approaches such as VQGAN+CLIP and DALL·E Mini (later renamed Craiyon), made similar systems more accessible to the public. Dream by Wombo was released at the end of 2021, followed by the releases of Midjourney and Stable Diffusion in 2022. In November 2022, ChatGPT was released to the public. By 2023, it popularized generative AI for general-purpose text-based tasks.
Bats rely on skin on their wings to generate lift and thrust used in flight. Therefore, the structure of the bat wing skin is different from the skin of the bat body. Bat wing skin consists of two thin layers of epidermis with a thin layer of dermis/hypodermis located between the epidermal layers whereas the skin of the bat body consists of a single layer of epidermis with a thicker layer of dermis internal to the epidermis. Within the dermal and epidermal layer of bat wing skin, the connective tissue and muscle fibers provide the structural support. The connective tissue fibers within bat wing skin consists of collagen and elastin fiber bundles arranged in a "regular mesh like scaffolding", which the nerves, skeletal muscle fibers and blood vessels embed themselves into. Of the muscles that insert themselves into the mesh scaffolding, larger muscles anchor the skin to the bone and control the membrane tension and camber of the bat wing during flight, whereas smaller muscles, which originate from within the mesh scaffolding, attach to collagen fibers within the fiber network and modulate bone loading and allow for precise control of wing shape and tension. As seen in snakes, local structural differences within the arrangement of the fibers change the mechanical properties of local area, but there are general characteristics that describe the mechanical behavior of bat wing skin.
(SC) subcutaneous (most applicable to real bites): 0.32 mg/kg, 0.28 mg/kg. (IV) intravenous: 0.25 mg/kg, 0.011 mg/kg. (IP) intraperitoneal: 0.30 mg/kg (average), 0.941 mg/kg. 0.05 mg/kg (the last quote does not make it clear if it is either intravenous or intraperitoneal). It is estimated that only 10 to 15 mg will kill a human adult; however, its bites deliver about 120 mg of venom on average, although they may deliver up to 400 mg of venom in a single bite. Severe neurotoxicity invariably ensues rapidly. This is because of several factors, including the high potency of the venom, and the unusual composition of synergistic toxins contained within the venom, which bring on severe symptoms of envenomation and death much faster than any other snake venom. In addition, the snake itself possesses the most advanced, evolved, and efficient venom delivery apparatus among all venomous snakes, and the most advanced and evolved dentition of all elapids. Black mambas possess the longest fangs of any elapid, which average around 13.1 millimeters (0.52 in), but may grow as long as 22 millimeters (0.87 in). Another feature that distinguishes the dentition and venom delivery apparatus of this species from all other elapids, as well as other species of venomous snake including those of the family Viperidae, is that the fangs are positioned well forward at the most anterior position possible in its mouth – right up in the front of the upper jaw.
Sources: en.wikipedia.org
=== Growrooms === With pest problems reduced and nutrients constantly fed to the roots, productivity in hydroponics is high; however, growers can further increase yield by manipulating a plant's environment by constructing sophisticated growrooms.
This was important for the introduction of new emergency acts: the grand coalition gave the ruling parties the two-thirds majority of votes required for their ratification. These controversial acts allowed basic constitutional rights such as freedom of movement to be limited in case of a state of emergency.
==== MeSH D12.776.835.700.350 – gtp phosphohydrolase-linked elongation factors ==== MeSH D12.776.835.700.350.200 – peptide elongation factor g MeSH D12.776.835.700.350.700 – peptide elongation factor tu MeSH D12.776.835.700.350.800 – peptide elongation factor 1 MeSH D12.776.835.700.350.850 – peptide elongation factor 2
=== Legal status === Effective from May 2019, China officially classified all forms of fentanyl as controlled narcotics. In the UK, fentanyl is classified as a controlled Schedule II, Class A drug under the Misuse of Drugs Act 1971. In the Netherlands, fentanyl is a List I substance of the Opium Law. In the US, fentanyl is a Schedule II controlled substance per the Controlled Substances Act. Distributors of Abstral are required to implement an FDA-approved risk evaluation and mitigation strategy (REMS) program. In order to curb misuse, many health insurers have begun to require precertification and/or quantity limits for Actiq prescriptions. In Canada, fentanyl is considered a schedule I drug as listed in Canada's Controlled Drugs and Substances Act. Some fentanyl precursors, such as the piperidones (after October 2023) have been banned under its Precursor Control Regulations, which have been in place at least since November 2016.
=== Neurodegeneration === Pathological protein aggregation is a major hallmark of multiple neurodegenerative diseases. O-GlcNAc on various proteins has been found to play roles in suppressing protein aggregation, motivating clinical efforts to inhibit OGA and elevate cellular O-GlcNAc levels. This strategy is being evaluated by companies for Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, and amyotrophic lateral sclerosis (ALS). Multiple companies have advanced OGA inhibitors into the clinic including Alectos Therapeutics, Asceneuron, Biogen, Eli Lilly, and Merck.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.